Advances in aptamers screening and the applications in cancer therapy

Abstract

Zheng Siqi, Guo Ting, Wang Jing, Tian Yinghong, Zhang Xingmei. Advances in aptamers screening and the applications in cancer therapy[J]. Journal of International Oncology, 2025, 52(5): 304-308.

References39

[1]	Qian S, Chang D, He S, et al. Aptamers from random sequence space: accomplishments, gaps and future considerations[J].Anal Chim Acta,2022,1196: 339511. DOI:10.1016/j.aca.2022.339511.
[2]	Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands[J].Nature,1990,346(6287): 818-822. DOI:10.1038/346818a0.
[3]	Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase[J].Science,1990,249(4968): 505-510. DOI:10.1126/science.2200121. pmid:2200121
[4]	Wu L, Zhang Y, Wang Z, et al. Aptamer-based cancer cell analysis and treatment[J].ChemistryOpen,2022,11(10): e202200141. DOI:10.1002/open.202200141.
[5]	Zhang Y, Lai BS, Juhas M. Recent advances in aptamer discovery and applications[J].Molecules,2019,24(5): 941. DOI:10.3390/molecules24050941.
[6]	Zhu C, Feng Z, Qin H, et al. Recent progress of SELEX methods for screening nucleic acid aptamers[J].Talanta,2024,266(Pt 1): 124998. DOI:10.1016/j.talanta.2023.124998.
[7]	Lyu C, Khan IM, Wang Z. Capture-SELEX for aptamer selection: a short review[J].Talanta,2021,229: 122274. DOI:10.1016/j.talanta.2021.122274.
[8]	Zhu C, Yang G, Ghulam M, et al. Evolution of multi-functional capillary electrophoresis for high-efficiency selection of aptamers[J].Biotechnol Adv,2019,37(8): 107432. DOI:10.1016/j.biotechadv. 2019.107432.
[9]	Jing M, Bowser MT. Isolation of DNA aptamers using micro free flow electrophoresis[J].Lab Chip,2011,11(21): 3703-3709. DOI:10.1039/c1lc20461k. pmid:21947169
[10]	Li Y, Tam WW, Yu Y, et al. The application of aptamer in biomarker discovery[J].Biomark Res,2023,11(1): 70. DOI:10. 1186/s40364-023-00510-8.
[11]	Sun X, Xie L, Qiu S, et al. Elucidation of CKAP4-remodeled cell mechanics in driving metastasis of bladder cancer through aptamer-based target discovery[J].Proc Natl Acad Sci U S A,2022,119(16): e2110500119. DOI:10.1073/pnas.2110500119.
[12]	Yu F, Chen J, Wang Z, et al. Screening aptamers for serine β- lactamase-expressing bacteria with precision-SELEX[J].Talanta,2021,224: 121750. DOI:10.1016/j.talanta.2020.121750.
[13]	Nikam PS, Palachandra S, Kingston JJ. In vitro selection and characterization of ssDNA aptamers by cross-over SELEX and its application for detection of S. Typhimurium[J].Anal Biochem,2022,656: 114884. DOI:10.1016/j.ab.2022.114884.
[14]	Duan Y, Zhang C, Wang Y, et al. Research progress of whole-cell-SELEX selection and the application of cell-targeting aptamer[J].Mol Biol Rep,2022,49(8): 7979-7993. DOI:10.1007/s11033-022-07317-0. pmid:35274201
[15]	Wen K, Chen Y, Meng X, et al. A microfluidic dual-aptamer sandwich assay for rapid and cost-effective detection of recombinant proteins[J].Microchem J,2023,188: 108454. DOI:10.1016/j.microc.2023.108454.
[16]	Chang D, Wang Z, Flynn CD, et al. A high-dimensional microfluidic approach for selection of aptamers with programmable binding affinities[J].Nat Chem,2023,15(6): 773-780. DOI:10.1038/s41557-023-01207-z. pmid:37277648
[17]	Qiao N, Li J, Wu X, et al. Speeding up in vitro discovery of structure-switching aptamers via magnetic cross-linking precipitation[J].Anal Chem,2019,91(21): 13383-13389. DOI:10.1021/acs.analchem.9b00081. pmid:31580650
[18]	Liu J, Duan Q, Shao Z, et al. Formaldehyde cross-linking-assisted phase separation for protein aptamer selection[J].Anal Chem,2023,95(16): 6700-6708. DOI:10.1021/acs.analchem.3c00434. pmid:37052573
[19]	Komarova N, Barkova D, Kuznetsov A. Implementation of high-throughput sequencing (HTS) in aptamer selection technology[J].Int J Mol Sci,2020,21(22): 8774. DOI:10.3390/ijms21228774.
[20]	Guo L, Song Y, Yuan Y, et al. Identification of nucleic acid aptamers against lactate dehydrogenase via SELEX and high-throughput sequencing[J].Anal Bioanal Chem,2021,413(17): 4427-4439. DOI:10.1007/s00216-021-03397-2. pmid:34028561
[21]	Ferreira D, Barbosa J, Sousa DA, et al. Selection of aptamers against triple negative breast cancer cells using high throughput sequencing[J].Sci Rep,2021,11(1): 8614. DOI:10.1038/s41598-021-87998-y.
[22]	Yazdian-Robati R, Bayat P, Oroojalian F, et al. Therapeutic applications of AS1411 aptamer, an update review[J].Int J Biol Macromol,2020,155: 1420-1431. DOI:10.1016/j.ijbiomac.2019.11.118. pmid:31734366
[23]	Mehrnia SS, Hashemi B, Mowla SJ, et al. Radiosensitization of breast cancer cells using AS1411 aptamer-conjugated gold nanoparticles[J].Radiat Oncol,2021,16(1): 33. DOI:10.1186/s13014-021-01751-3.
[24]	Huang BT, Lai WY, Yeh CL, et al. AptBCis1, an aptamer-cisplatin conjugate, is effective in lung cancer leptomeningeal carcinomatosis[J].ACS Nano,2024,18(41): 27905-27916. DOI:10.1021/acsnano.4c04680.
[25]	Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma[J].Hepatology,2023,77(5): 1773-1796. DOI:10.1002/hep.32740.
[26]	Wang Z, Wu C, Liu J, et al. Aptamer-mediated hollow MnO₂for targeting the delivery of sorafenib[J].Drug Deliv,2023,30(1): 28-39. DOI:10.1080/10717544.2022.2149897.
[27]	Zhang Y, Bi J, Huang J, et al. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications[J].Int J Nanomedicine,2020,15: 6917-6934. DOI:10.2147/ijn.S264498.
[28]	张渊, 白芷玉, 李琪, 等. 外泌体在恶性肿瘤中的研究现状[J].国际肿瘤学杂志,2023,50(8): 484-488. DOI:10.3760/cma.j.cn371439-20230315-00092.
[29]	Han Q, Xie QR, Li F, et al. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer[J].Theranostics,2021,11(13): 6526-6541. DOI:10. 7150/thno.53886. pmid:33995674
[30]	Tran PHL, Wang T, Yin W, et al. Aspirin-loaded nanoexosomes as cancer therapeutics[J].Int J Pharm,2019,572: 118786. DOI:10.1016/j.ijpharm.2019.118786.
[31]	Yang Y, Sun X, Xu J, et al. Circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy[J].ACS Nano,2020,14(8): 9562-9571. DOI:10.1021/acsnano. 9b09884. pmid:32584540
[32]	Peng JJ, Wang L, Li Z, et al. Metabolic challenges and interventions in CAR T cell therapy[J].Sci Immunol,2023,8(82): eabq3016. DOI:10.1126/sciimmunol.abq3016.
[33]	Liu CG, Wang Y, Liu P, et al. Aptamer-T cell targeted therapy for tumor treatment using sugar metabolism and click chemistry[J].ACS Chem Biol,2020,15(6): 1554-1565. DOI:10.1021/acschembio.0c00164.
[34]	Menon AP, Villanueva H, Meraviglia-Crivelli D, et al. CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer[J].Mol Ther Nucleic Acids,2024,35(2): 102198. DOI:10.1016/j.omtn.2024.102198.
[35]	Porreca I, Blassberg R, Harbottle J, et al. An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation[J].Mol Ther,2024,32(8): 2692-2710. DOI:10.1016/j.ymthe.2024.06.033.
[36]	Liu Y, Qian X, Ran C, et al. Aptamer-based targeted protein degradation[J].ACS Nano,2023,17(7): 6150-6164. DOI:10. 1021/acsnano.2c10379.
[37]	He S, Gao F, Ma J, et al. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer[J].Angew Chem Int Ed Engl,2021,60(43): 23299-23305. DOI:10.1002/anie.202107347.
[38]	Zhang L, Li L, Wang X, et al. Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin[J].Mol Ther Nucleic Acids,2022,30: 66-79. DOI:10.1016/j.omtn.2022.09.008.
[39]	Wang Y, Yang G, Zhang X, et al. Antitumor effect of anti-c-Myc aptamer-based PROTAC for degradation of the c-Myc protein[J].Adv Sci (Weinh),2024,11(26): 2309639. DOI:10.1002/advs. 202309639.

Advances in aptamers screening and the applications in cancer therapy

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References39

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Guo Haiyang, Hong Yonggang, Hao Liqiang.Role and research progress of ferroptosis in colorectal cancer[J]. Journal of International Oncology, 2025, 52(5): 319-324.
[2]	Yu Yang, Tang Shimin, Yang Lu, Li Na.Research progress in treatment strategies and prognostic factors for stage pT_2-3N₀M₀thoracic esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2025, 52(1): 43-47.
[3]	Han Yi, Zhang Tongmei, Qi Fei, Zhang Yong.Advances in clinical molecular diagnosis and treatment of pulmonary large cell neuroendocrine carcinoma[J]. Journal of International Oncology, 2024, 51(7): 468-473.
[4]	Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao.Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma[J]. Journal of International Oncology, 2024, 51(4): 239-244.
[5]	Tao Jin, Kan Junnan, Yang Caixia, Liu Yan, Lyu Yijie, Wei Junhui, Li Xianglin.Progress of manganese-based nanomaterials in breast cancer diagnosis and treatment[J]. Journal of International Oncology, 2024, 51(10): 645-649.
[6]	Shi Yue, Li Shen, Feng Jifeng.Treatment options for colorectal cancer primary lesions with unresectable metastases at risk of acute abdomen[J]. Journal of International Oncology, 2021, 48(11): 693-697.
[7]	Dong Fang, Xue Jincai, Wang Yunsheng, Liu Qinjiang.Progress of external beam radiotherapy for thyroid cancer[J]. Journal of International Oncology, 2019, 46(11): 641-648.
[8]	WANG Jin, WANG Jing, LIAO Shi-Qi, ZENG Jia-Yu.Aptamers selection for tumor based on cellSELEX and its application in tumor diagnosis and treatment[J]. Journal of International Oncology, 2018, 45(5): 304-307.
[9]	Zhou Jin, Wu Jie, Zhang Huibo, Chen Min.Therapy for elderly patients with advanced nonsmall cell lung cancer[J]. Journal of International Oncology, 2018, 45(12): 756-759.
[10]	PENG Yong-Hua, PENG Li, LIANG Zhi-Man, ZHANG Xing-Mei.Application of aptamer in the study of cancer stem cells[J]. Journal of International Oncology, 2017, 44(8): 672-675.
[11]	Chen Dalei, Shen Yanyan, Lin Chuanqi, Wang Xiaohui, Shi Hao, Guo Guilong.Treatment protocols of local-regional recurrence after breast cancer surgery[J]. Journal of International Oncology, 2017, 44(12): 929-932.
[12]	Kou Zhewen, Peng Li, Zhang Xingmei.Nucleic acid aptamer and its research progress in glioma[J]. Journal of International Oncology, 2017, 44(1): 38-40.
[13]	LIANG Jian-Wei, YAN Ru-Ping, WANG Jian-Song.Nucleic acid aptamer for caner therapeutics and diagnostics[J]. Journal of International Oncology, 2016, 43(7): 519-522.
[14]	Shi Yusheng, Peng Yonghua, Sheng Shuyue, Zhang Xingmei.Aptamers as molecular probes in tumor molecular imaging[J]. Journal of International Oncology, 2016, 43(11): 838-840.
[15]	Li Ying, Fang Xiaomeng, Jiang Da, Dong Qian, Zhang Zengye, Zheng Fei.Meta analysis of brain metastases ideal treatment mode[J]. Journal of International Oncology, 2015, 42(2): 103-108.